title: Ex-vivo expansion of NK cells: what is the priority--high yield or high purity?
authors.affiliation: National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Berg
authors.forename: Richard
authors.initials: R
authors.lastname: Childs
mesh_terms: D000943:Antigens, Differentiation; D019149:Bioreactors; D019002:CD56 Antigen / Q000096:biosynthesis; D018929:Cell Culture Techniques; D049109:Cell Proliferation; D003602:Cytotoxicity, Immunologic; D006086:Graft vs Host Disease / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D016131:Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation
chemical_list: D000943:Antigens, Differentiation; D019002:CD56 Antigen